Development of New Benzylpiperazine Derivatives as σ<sub>1</sub> Receptor Ligands with <i>in Vivo</i> Antinociceptive and Anti-Allodynic Effects
作者:Giuseppe Romeo、Federica Bonanno、Lisa L. Wilson、Emanuela Arena、Maria N. Modica、Valeria Pittalà、Loredana Salerno、Orazio Prezzavento、Jay P. McLaughlin、Sebastiano Intagliata
DOI:10.1021/acschemneuro.1c00106
日期:2021.6.2
propan-1-one (15) showed the highest σ1R receptor affinity (Ki σ1 = 1.6 nM) among the series with a significant improvement of the σ1R selectivity (Ki σ2/Ki σ1= 886) compared to the lead compound 8 (Ki σ2/Ki σ1= 432). Compound 15 was further tested in a mouse formalin assay of inflammatory pain and chronic nerve constriction injury (CCI) of neuropathic pain, where it produced dose-dependent (3–60 mg/kg
σ-1 受体 (σ 1 R) 调节伤害性信号传导,推动寻找选择性拮抗剂,以利用这一有前景的靶点来治疗疼痛。在这项研究中,设计、合成了一系列新的苄基哌嗪基衍生物,并对其对 σ 1 R 的亲和力和对 σ-2 受体 (σ 2 R) 的选择性进行了表征。值得注意的是,3-环己基-1-4-[(4-甲氧基苯基)甲基]哌嗪-1-基}丙-1-酮 ( 15 ) 显示出最高的 σ 1 R 受体亲和力 ( K i σ 1 = 1.6 nM)与先导化合物8 ( K i σ 2 / K i σ 1 = 432) 相比,该系列中 σ 1 R 选择性 ( K i σ 2 / K i σ 1 = 886) 有显着提高。化合物15在炎症性疼痛和神经性疼痛的慢性神经缩窄损伤 (CCI) 的小鼠福尔马林测定中进行了进一步测试,其中它产生剂量依赖性(3-60 mg/kg,腹腔注射)的镇痛和抗异常疼痛作用。此外,化合物15在转棒测定中没有表现出显着效果,表明这种
EBI2 MODULATORS
申请人:SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
公开号:US20160214951A1
公开(公告)日:2016-07-28
Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
Novel Piperazine Amides of Cinnamic Acid Derivatives as Tyrosinase Inhibitors
Background: A series of novelcinnamicacid piperazine amidederivatives has been designed and synthesized, and their biological activities were also evaluated as potential tyrosinase inhibitors. Methods: Compounds 9, 11 and 17 showed the most potent biological activity (IC50 = 66.5, 61.1 and 66 µM, respectively). In silico docking simulation was performed to position compound 11 into the Agaricus